Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09UXP
|
|||
| Former ID |
DIB011493
|
|||
| Drug Name |
AZD-1744
|
|||
| Synonyms |
Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca
Click to Show/Hide
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 3 (CCR3) | Target Info | Modulator | [2] |
| Histamine H1 receptor (H1R) | Target Info | Modulator | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Viral carcinogenesis | ||||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL3 Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| Histamine receptors | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| IL1 and megakaryotyces in obesity | ||||
| IL-3 Signaling Pathway | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Monoamine GPCRs | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025772) | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.